35.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$35.37
Offen:
$34.35
24-Stunden-Volumen:
631.66K
Relative Volume:
0.80
Marktkapitalisierung:
$3.18B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-5.4297
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
-9.67%
1M Leistung:
-14.86%
6M Leistung:
-34.53%
1J Leistung:
-25.38%
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RARE
Ultragenyx Pharmaceutical Inc
|
35.13 | 3.18B | 522.75M | -558.99M | -439.53M | -6.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
2021-08-19 | Eingeleitet | UBS | Sell |
2021-07-15 | Eingeleitet | Guggenheim | Neutral |
2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
2021-03-02 | Fortgesetzt | Stifel | Buy |
2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
2019-08-02 | Fortgesetzt | Wedbush | Outperform |
2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-02-22 | Fortgesetzt | Raymond James | Outperform |
2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
2018-05-10 | Eingeleitet | Goldman | Neutral |
2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
2018-02-21 | Bestätigt | Stifel | Buy |
2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
2017-12-05 | Bestätigt | Barclays | Equal Weight |
2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
How another firm's FDA approval could mean a big win for Denali Therapeutics - The Business Journals
Winners and wishers: 9 potential Bay Area drug approvals coming this year - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga
Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks
Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia
Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa
Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com
Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan
Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace
Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR
Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St
Ultragenyx pharmaceutical CFO sells $72,114 in common stock By Investing.com - Investing.com Canada
Ultragenyx pharmaceutical CFO sells $72,114 in common stock - Investing.com India
Ultragenyx Pharmaceutical, Inc. to Host Earnings Call - ACCESS Newswire
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline - TipRanks
FDA grants priority review to gene therapy for Sanfilippo type A - Sanfilippo News
Ultragenyx Pharmaceutical Inc Reports Q4 2024 Revenue of $165 Mi - GuruFocus.com
Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock By Investing.com - Investing.com Australia
Ultragenyx’s chief accounting officer sells $40,710 in stock By Investing.com - Investing.com Australia
Ultragenyx pharmaceutical executive sells $607,881 in stock By Investing.com - Investing.com Australia
Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock - Investing.com India
Ultragenyx EVP Eric Crombez sells $376,584 in stock - Investing.com India
Ultragenyx EVP Eric Crombez sells $376,584 in stock By Investing.com - Investing.com Australia
Ultragenyx pharmaceutical EVP sells $635,836 in stock - Investing.com India
Ultragenyx pharmaceutical EVP sells $635,836 in stock By Investing.com - Investing.com Canada
Ultragenyx pharmaceutical executive sells $607,881 in stock - Investing.com
Ultragenyx CEO Emil Kakkis sells $4.15 million in stock By Investing.com - Investing.com UK
Ultragenyx’s chief accounting officer sells $40,710 in stock - Investing.com
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Ultragenyx EVP Karah Parschauer sells $128,223 in stock By Investing.com - Investing.com Canada
Ultragenyx Loses Bid To Toss Suit Over Henrietta Lacks' Cells - Law360
Ultragenyx EVP Karah Parschauer sells $128,223 in stock - Investing.com India
(RARE) Technical Pivots with Risk Controls - Stock Traders Daily
Y Intercept Hong Kong Ltd Raises Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical’s (RARE) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):